The Cancer Moonshot aimed to halve cancer deaths by 2047 during Trump's return to the White House. Despite substantial federal funding for cancer research, Trump's administration halted NIH grant-making for two months, affecting approximately $1.5 billion in funding and clinical trials. Thousands of FDA and NIH employees were laid off, and a hiring freeze at the Department of Veterans Affairs put $35 million in research at risk. Cuts to medical research programs by Republicans further complicated the status of cancer research, leading to confusion in the field.
Trump's decision to pause NIH grant-making for over two months halted approximately $1.5 billion in funding, disrupting clinical trials for new cancer drugs and research.
Federal funding for cancer research was unprecedented prior to Trump's administration, with substantial contributions from various agencies, including the NIH and the Department of Defense.
The hiring freeze at the Department of Veterans Affairs jeopardized $35 million in ongoing cancer research, while the EPA was directed to cancel existing grants affecting health research.
Significant cuts were made to Congressionally Directed Medical Research Programs by Republicans, severely impacting funding for cancer research initiatives across multiple organizations.
Collection
[
|
...
]